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Objective: To determine the potential drug–drug interactions between anti-malarial
candidate 97/78 and anti-tubercular drug rifabutin in-vivo in rats followed by in-vitro
investigation of the underlying mechanisms of drug interaction.
Methods: Single oral dose study was conducted in male and female rats at 40 mg/kg and
70 mg/kg for 97/78 and rifabutin respectively.
Results: It was reported that rifabutin co-administration altered pharmacokinetics of 97/
63 (active metabolite of 97/78). A signiﬁcant decrease was reported in the systemic
exposure of 97/63 by a factor of 3–4. The AUC0-last values were (4.03 ± 0.60) and
(5.44 ± 1.15) mg h mL−1 upon 97/78 administration alone, while the values were
decreased to (1.13 ± 0.10) and (1.23 ± 1.13) mg h mL−1 upon rifabutin co-administration
in male and female rats respectively. Statistically signiﬁcant differences were also re-
ported in Cmax and Tmax values upon rifabutin co-administration. In-vitro drug meta-
bolism study in rat liver microsomes has shown that the metabolism of 97/63 was
increased by 10%–12% upon rifabutin co-incubation. The extent of plasma protein
binding of 97/63 was found to be decreased from 54%-55% to 6%–8% upon rifabutin
addition.
Conclusions: It was concluded that rifabutin co-administration altered PK parameters of
97/63 in SD rats. However, no intersex inﬂuences were reported in the interaction pattern.
The results obtained in the in-vivo study were well correlated with the in-vitro ﬁndings
and can further be applied to explore other aspects of potential drug interactions between
these two drugs.1. Introduction
Tuberculosis and malaria co-epidemics are very prevalent in
most of the tropical and sub-tropical areas of the world that
creates serious damage to socio-economic status besides public
health concerns. More than six million people are killed by the
co-infection of these two diseases with AIDS annually [1–3].
Patients are supposed to take co-medications for malaria andtuberculosis simultaneously, which may give rise to serious
drug–drug interactions (DDIs). It has been reported that the
greater the number of drugs is given to a patient, the more the
risk of potential drug interactions. Incidences of such drug in-
teractions raises up to 7% in those patients taking 6–10 drugs
and 40% in those taking 16–20 drugs daily [4].
It is important to explore drug metabolism and pharmacoki-
netic (DMPK) properties of drug candidate in early stages of
drug discovery and development. Besides DMPK, DDIs are
routinely incorporated in the early phases of drug development
pathway from a safety point of views. For this, preclinical
studies are often carried out in experimental animals. From the
preclinical data, the allometric scaling approaches that consider
important anatomical and physiochemical variables in higher
species as a power function of the body weight across species
may be used to predict human pharmacokinetics (PK) aspects [5–
8]. There are a number of gender-dependent and gender-speciﬁcopen access article under the CC BY-NC-ND
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Physiological and anatomical differences between the genders of
a species are the responsible factors inﬂuencing PK of a drug
differently [9,10].
In the present study, in-vivo drug interactions were investi-
gated between a novel trioxane anti-malarial candidate 97/78
(phase I clinical trials completed) and antitubercular drug rifa-
butin (interacting drug). Single oral dose drug interaction studies
were performed in male and female Sprague Dawley (SD) rats to
determine the changes in PK and intersexual interaction pattern
of 97/78 upon rifabutin co-administration. The results of single
dose interaction study were analyzed and in-vitro studies were
performed to ﬁnd out the mechanism behind the existence of
these in-vivo interactions.
2. Materials and methods
2.1. Chemicals
Rifabutin was obtained as a gift sample from Lupin (Pune),
India. Reference standards (purity > 98%) of 97/78, 97/63
(Figure 1a) and internal standard (IS) arteether (Figure 1b) were
obtained from the medicinal chemistry division, CDRI, Luck-
now, India. Blank plasma was collected from drug free healthy
male and female SD rats procured from the Laboratory Animal
Services Division, CDRI. All other chemicals and reagents were
of analytical liquid chromatographic (LC) grade. Dextran coated
charcoal for plasma protein binding study was obtained from
Sigma chemicals USA. Dulbecco's Phosphate buffered saline
(Ca2+ and Mg2+ free) was purchased from Hi media Lab. Pvt.
Ltd., Mumbai. For metabolism stability studies, Tris (hydrox-
ymethyl) aminomethane (tris base), KCl, MgCl2$6H2O, bovine
serum albumin and a reduced form of b-nicotinamide adenine
dinucleotide phosphate were purchased from Sisco Research
Laboratory (Mumbai, Maharashtra, India). 1-
aminobenzotriazole, Bradford reagent and diethyl ether were
procured from Qualigens (Mumbai), Loba Chemie (Mumbai)
and TKM Pharma (Hyderabad, AP, India), respectively. Rat
liver microsomes were prepared by using the methods adapted
from literature [11].
2.2. Subjects and study design
Healthy male and female SD rats (250–270 g) free from any
symptoms of pathophysiology were obtained from LaboratoryFigure 1. Chemical structure of 97/78, 97/63 (a) and IS a-arteether (b).Animal Services Division, CDRI (approval no. IAEC/2012/
91Ns) were allowed to acclimatize for 3 d in ventilated poly-
propylene cases at standard laboratory conditions [12 h light–
dark cycle, (22 ± 2) C temperature and (55 ± 5)% relative
humidity] before the commencement of study. Subjects were
fasted for about 10–12 h before and 2 h following drug
administration with water ab libitum. Animals were cared in
accordance with principles of the guide for care and use of
laboratory animals [Department of health education and welfare,
number (NIH) 85-32].
2.2.1. In-vivo studies
We conducted a parallel design, single dose/single dose
pharmacokinetic interaction study that comprised of two
groups of animals. One group of subjects was orally admin-
istered with 97/78 at 40 mg/kg, while other group received 97/
78 followed by rifabutin at 40 mg/kg dose. Sparse sampling
approach was used to collect blood samples through cardiac
puncture (ﬁrst sample) and inferior vena cava (terminal sam-
ple). Blood samples were collected before dosing (0 time
point) and up to 96 h post dose. Blood samples were stored in
ice until centrifugation. Plasma was separated by centrifuga-
tion at 2200 g for 5 min and stored at −60 C until analysis.
Analysis was performed within a month of sample collection.
All experimental procedures were approved and performed in
accordance with the guidelines of the Institutional Animal
Experimentation Ethics Committee (IAEC/CPCSEA/Regula-
tory Agencies).
The formulations used in the study were aqueous suspension
of 97/78 and rifabutin in 0.25% carboxy methyl cellulose. Both
the formulations were subjected to quality control checks to
ensure strength and content uniformity. The strength of the
formulations for 97/78 and rifabutin was 20 and 35 mg/mL
respectively.
2.2.2. In-vitro studies
In-vitro studies were then conducted to ﬁnd out the mecha-
nism behind the in-vivo study observations. In-vitro plasma
protein binding studies were conducted to ﬁnd out the changes
in the plasma protein bindings of 97/78, while in-vitro drug
metabolism studies were conducted to ﬁnd out the interactions at
the level of metabolism.
Protein binding was estimated using modiﬁed charcoal
adsorption method adopted from literature [12]. The study was
conducted in three replicates each at 100 and 1000 ng/mL
Table 1
Comparative PK parameters of 97/63 after 97/78 alone and co-
administration with rifabutin in male and female rats (mean ± SEM,
n = 3).
PK
parameters
97/78 alone 97/78 + Rifabutin
Male rats Female rats Male rats Female rats
Cmax
(mg/mL)
0.56 ± 0.18 0.79 ± 0.10 0.13 ± 0.03# 0.17 ± 0.03#
Tmax (h) 5.33 ± 0.76 6.00 ± 0.00 2.25 ± 0.86
# 1.83 ± 1.25#
AUC0-last
(mg h mL−1)
4.03 ± 0.60 5.44 ± 1.15 1.13 ± 0.10# 1.23 ± 1.13#
T1/2 (h) 6.49 ± 1.64 6.09 ± 2.40 4.30 ± 1.13 6.23 ± 1.09
MRT (h) 11.58 ± 1.55 11.65 ± 1.36 10.17 ± 0.82 10.12 ± 1.30
#Statistically signiﬁcantly different (P < 0.05), when compared to base
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two sets, one set involving spiked 97/63 only, while other set
spiked with 97/63 and rifabutin. The spiked plasma was
allowed to equilibrate for 20 min before the commencement of
study. Serial samples (200 mL) were withdrawn at 0, 5, 10 and
15 min in polypropylene centrifuge tubes and centrifuged at
10000 g for 4 min at 37 C. Supernatant was collected and
stored at −70 C till LC-MS/MS analysis.
97/63 alone, 97/63 with rifabutin and testosterone (as a
control) were incubated separately in a shaking water bath in an
incubation mixture of 0.1 M Tris buffer, 5 mM MgCl2$6H2O
and 0.4 mg/mL of rat microsomes at [(37 ± 1) C]. The con-
centrations used for incubation were 2 mM, for 97/63, 5 mM for
rifampicin and 2 mM for testosterone. b-nicotinamide adenine
dinucleotide phosphate (2 mM) was pre-incubation for 4 min
before the commencement of the study. Two sets of control were
used in the study. In the ﬁrst set, b-nicotinamide adenine dinu-
cleotide phosphate was substituted with an equal volume of Tris
buffer, while other set of controls was incubated consisting of all
incubation components except microsomes. The reactions were
quenched with ice cold ACN spiked with 4 mM of IS at different
time points ranging from 0 to 60 min. Samples were processed
and supernatant was subjected to UFLC analysis. Before starting
these experiments, non-speciﬁc binding of drug 97/63 with
microsomal proteins was determined by incubating 97/63 in an
optimized incubation milieu (0.4 mg/mL of rat liver microsomes
at [(37 ± 1) C] in a shaking water bath at varying concentrations
ranging from 0.2 to 30 mM for 5 min.
2.3. Pharmacokinetic sample processing and
bioanalysis
All study samples were quantitatively estimated for the
determination of 97/63 (active metabolite of 97/78). A partially
validated method in Q-trap 5500 LC–MS/MS mass spectrometer
(Applied Biosystems, MDS Sciex, USA) with Analyst 1.6
software was used to determine plasma concentration of 97/63.
The assay was linear over the range 0.625–80 ng/mL 10 mL of
IS was spiked into each study sample followed by a single step
protein precipitation method using acetonitrile. Mass spectrom-
etry was performed in positive mode electro spray ionization
with capillary voltage 5.5 KV. The MS/MS transitions of m/z
418.2/ 119.1 and 330.3/ 267.4 were used to quantify 97/63
and IS respectively. HPLC elution was carried out in isocratic
mode with mobile phase comprising of 80:20 (v/v) ACN (0.1%
formic acid) and ammonium acetate buffer (10 mM, pH 4.0)
using a Phenomenex C 18 Columbus (50 mm × 2 mm, 5 m
particle size) equipped with a security guard cartridge. Separa-
tion was achieved at 450 mL/min ﬂow rate with injection volume
of 10 mL [13,14]. Processed sample were maintained in auto
sampler at 4 C.
2.4. Statistical analysis
The study endpoints examined were area under the curve
(AUC0-last), maximum plasma concentration (Cmax), time to
attain Cmax (Tmax), elimination half life (T1/2) and mean resi-
dence time (MRT) and the relative bioavailability (RB). The PK
parameters were calculated by non-compartmental analysis us-
ing Winnonlin software (Version 1.5, Pharsight Corporation).
All results were expressed as mean ± SEM.RB was calculated as:
% RB=
AUCco − admin
AUCcontrol
× 100 (1)
The results of the in-vitro metabolic study were expressed as
the % drug remaining, which was calculated as:
% Drug remaining =
drug conc: after incubation
drug conc: at t = 0
× 100 (2)
The % plasma protein binding was calculated as,
% Plasma protein binding =
Drug conc: analyzed at t = 0
Spiked plasma conc:
× 100 (3)
It has been reported that 97/78 (prodrug) converts into 97/63
(active metabolite) within a few minutes in biological matrices
like plasma [15], thus samples were analyzed for the
determination of 97/63, post 97/78 oral dose administration
alone and with rifabutin in male and female rats. All the
results are expressed as mean values ± SEM, n = 4. The
values of various PK parameters for 97/78 alone and co-
administration with rifabutin were statistically compared with
‘2-tailed Students t-test’. The values were considered
statistically signiﬁcantly different for P < 0.05.
3. Results
3.1. Pharmacokinetic drug interaction studies
3.1.1. Male rats
Table 1 summarizes PK parameters of 97/63 post 97/78
administration alone and with rifabutin in male rats. The value of
Cmax was (0.56 ± 0.18) mg/mL at corresponding Tmax of
(5.33 ± 0.76) h when 97/78 was given alone. While upon co-
administration with rifabutin these values were found
(0.13 ± 0.03) mg/mL and (1.83 ± 1.25) h for Cmax and Tmax
respectively. Figure 2 represents plasma concentration–time
proﬁle of 97/63, when 97/78 was given alone and in combina-
tion with rifabutin in male rats.
3.1.2. Female rats
Table 1 summarizes PK parameters of 97/63 post 97/78
administration alone and with rifabutin in female rats. The value
of Cmax was (0.79 ± 0.10) mg/mL at corresponding Tmax of
(6.00 ± 0.00) h when 97/78 was given alone. While upon co-line PK proﬁle i.e., 97/78 administration alone.
Figure 2. Plasma concentration–time proﬁle of 97/63, upon 97/78 alone
and co-administration with rifabutin in male rats (n = 3).
Table 2
Percent plasma protein binding of 97/63, when spiked alone and with
rifabutin in SD rat plasma.
Spiked plasma
conc.(ng/mL)
% Plasma protein
binding
(97/63 spiked alone)
% Plasma protein
binding
(97/63 + Rifabutin)
P-value
100 55.33 ± 15.30 6.00 ± 1.00 0.03#
1000 54.66 ± 3.51 8.46 ± 1.20 0.02#
#Statistically signiﬁcantly different (P < 0.05).
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(0.17 ± 0.03) mg/mL and (1.83 ± 1.25) h for Cmax and Tmax
respectively. Figure 3 represents plasma concentration–time
proﬁle of 97/63, when 97/78 was given alone and in combina-
tion with rifabutin in female rats.
3.2. In-vitro drug interaction studies
3.2.1. In-vitro metabolism study
The experiment was carried out to determine the non-speciﬁc
binding of 97/63 with microsomal proteins. Non-speciﬁc bind-
ing was predicted from the disappearance of 97/63, upon its
incubation in an optimized incubation milieu of rat liver mi-
crosomes at various concentrations ranging from 0.1 to 20 mM
for 5, 10, 15 min. It revealed that there were non-signiﬁcant
protein-ligand interactions (data not shown). Figure 4 repre-
sents the % drug remaining upon incubation of 97/63 alone andFigure 3. Plasma concentration–time proﬁle of 97/63, upon 97/78 alone
and co-administration with rifabutin in female rats (n = 3).
Figure 4. Percent drug remaining in the incubation mixture containing 97/
63 alone and 97/63 with rifabutin.97/63 with rifabutin in optimized microsomal mixture at various
time intervals.
3.2.2. In-vitro plasma protein binding study
Table 2 represents % plasma protein binding of 97/63, when
spiked alone and with rifabutin in SD rat plasma. It was found
that there is slight increase in 97/63 metabolism when 97/63 was
incubated with rifabutin, compared to metabolism of 97/63 upon
alone incubation.
Figure 5 represents plasma concentration–time proﬁle of 97/
63, when 97/78 was given alone in male and female rats.
On the other hand, when 97/78 was co-administered with
rifabutin in male rats, statistically signiﬁcant differences were
reported in PK parameters of 97/63. It was observed that rifa-
butin co-administration reduced systemic exposure of 97/63 by a
factor of 3–4. In terms of AUC0-last, the value was
(4.03 ± 0.60) mg h mL−1 when 97/78 was given alone, while it
was decreased to (1.13 ± 0.10) mg h mL−1 upon co-
administration of rifabutin (Figure 6).Figure 5. Plasma concentration–time proﬁle of 97/63, when 97/78 was
given alone in male and female rats (mean ± SEM, n = 3).
Figure 6. Comparative AUCs of 97/63 upon 97/78 alone and co-
administration with rifabutin in male and female rats (mean ± SEM, n = 3).
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It is important to assess drug's safety and effectiveness during
the drug development phase in terms of drug interactions be-
tween investigational new drug and other drugs, so as to deﬁne
existence of any potential DDIs that in turn indicates the need
for additional therapeutics monitoring, dose adjustments and/or
contraindication to concurrent use [8]. Generally, the more the
number of drugs is given simultaneously the greater is the
potential of existence of DDIs. Keeping this in view, the study
was designed to determine the inﬂuence of rifabutin co-
administration on PK of 97/63 in male and female SD rats to
assess co-administered and intersexual differences.
It was found that 97/63 exhibited irregular plasma concen-
tration–time proﬁle in both the genders when 97/78 was either
given alone or with rifabutin. However, when 97/78 was given
alone, there were no intersexual differences in PK parameters of
97/63 i.e., both the genders exhibited similar PK proﬁle as
evident from the data in our study. Though, the value of Cmax in
female rats was found to be greater than male rats, but the dif-
ference was statistically non-signiﬁcant in terms of P > 0.05. All
other PK parameters were comparable for both the genders.
On the other hand, when 97/78 was co-administered with
rifabutin in male rats, statistically signiﬁcant differences were
reported in PK parameters of 97/63. It was observed that rifa-
butin co-administration reduced systemic exposure of 97/63 by a
factor of 3–4. In the similar manner, 3–4 fold decrease was
observed in Cmax which is explicitly indicated by the reduced
maximum plasma concentration of 97/63 from (0.56 ± 0.18) to
(0.13 ± 0.03) mg/mL upon rifabutin co-administration. Statisti-
cally signiﬁcant difference was also observed for Tmax values.
However, T1/2 and MRT values were comparable in both the
cases i.e. no signiﬁcant differences were observed.
Similarly, in female rats statistically signiﬁcant differenceswere
reported in PK parameters of 97/63 when 97/78 was co-
administered with rifabutin. It was observed that rifabutin co-
administration reduced systemic exposure of 97/63 by a factor of
3–4 like male rats. In terms of AUC0-last, the value was
(5.44 ± 1.15)mg$h$mL−1 when 97/78was given alone,while it was
decreased to (1.23 ± 1.13) mg h mL−1 upon co-administration of
rifabutin. Similar to male rats, maximum plasma concentration of
97/63 was reduced from (0.79 ± 0.10) to (0.17 ± 0.03) mg/mL−1
upon rifabutin co-administration in females too, indicating 3–4 fold
decrease in Cmax. Statistically signiﬁcant difference was observed
for Tmax values, while T1/2 and MRT values were comparable in
both the cases i.e. no signiﬁcant differences were observed.
As discussed earlier, no signiﬁcant differences (in terms of P-
value) were observed in PK parameters of 97/63 when 97/78
was given alone in male and female rats i.e., no intersexual in-
ﬂuences were reported. In the similar way, when rifabutin was
co-administered with 97/78, no intersex differences were
observed in the interaction pattern. In both the genders, 3–4 fold
decrease was reported in the systemic exposure of 97/63 upon
rifabutin co-administration with 97/78.
Overall, in-vivo studies have shown that there was a signif-
icant decrease in the systemic exposure of 97/63 upon rifabutin
co-administration in both the sexes. However, we hypothesized
that there could be multi-fold decrease in the systemic exposure
of 97/63, when 97/78 would have been co-administered with
rifabutin for long duration, since rifabutin is a moderate inducer
of hepatic CYP 3A. Thus, a multiple dose study may be required
to estimate and explore these aspects of interactions. The resultsof our study thus provide a basic information about the existence
of drug interactions between rifabutin and 97/78, which can be
used to conduct a multiple dose drug interaction study.
Further, we exercised to ﬁnd out the mechanism behind the
existence of interaction between 97/78 and rifabutin in-vitro. In-
vitrometabolism studies in rat liver microsome revealed that upon
rifabutin co-incubation with 97/63, there was 10%–12% increase
in themetabolism of 97/63 compared to 97/63 incubation alone. It
was found that about 48% of 97/63 get metabolized upon alone
incubation, compared to about 60% metabolism of 97/63 upon
rifabutin co-incubation. Thus, it could be reasoned that the
decreased systemic exposure of 97/63 upon rifabutin co-
administration can be in-part attributed to the increased meta-
bolism of 97/63 in presence of rifabutin. However, others factors
like interference in the absorption may be one among the reasons
responsible for decreased systemic exposure of 97/63.
In-vitro plasma protein binding studies have shown that there
was a very strong displacement of 97/63 from plasma proteins
when 97/63 was added with rifabutin into rat plasma. The extent
of plasma protein binding of 97/63 was found to be decreased
from 54% to 55% to a very low value of 6%–8% upon rifabutin
addition. It could be speculated from the results of plasma
protein bindings that upon displacement of 97/63 from plasma
proteins, the increased free drug concentration of 97/63 is more
susceptible to extraction by hepatocytes and hence more liable to
get metabolized by hepatic CYPs, thus contributing to the
decrease in the systemic exposure of 97/63.
From the above discussion, it could be concluded that rifabutin
co-administration altered PK parameters of 97/63 in SD rats. A
signiﬁcant decrease was reported in the systemic exposure of 97/
63, which indicates that the combination of these two drugs may
require some dose adjustments. However, no intersexual in-
ﬂuences were reported in the interaction pattern. The results of in-
vivo interaction studies were well correlated with in-vitro studies
and attempts were made to explain the mechanism behind the
existence of drug interaction. Though this was a single dose
interaction study in SD rats, multiple dose drug interaction study
can be conducted on the basis of the informations obtained in this
study. Further, clinical studies are required to determine the po-
tential of these drug interactions in humans. The results obtained
in this study can be extrapolated to humans using proper simu-
lation models keeping in view all the gender and species differ-
ences in relation to physio-chemical variations.
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